Securities code: 688336 securities abbreviation: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Announcement No.: 2022-009 Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Announcement of resolutions of the third meeting of the Fourth Board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of supervisors
The notice of the third meeting of the Fourth Board of supervisors was sent to all supervisors by telephone on February 11, 2022. The meeting was held by means of communication on February 16, 2022. Three supervisors should attend the meeting and three actually attended.
The meeting was presided over by Ms. Cao Hong, chairman of the board of supervisors. The convening and convening procedures, the qualifications of participants and the procedures for discussion and voting of the meeting were in accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”) and other laws, regulations, departmental rules and the relevant provisions of the Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) articles of Association (hereinafter referred to as the “articles of association”), The resolutions of the meeting are legal and effective.
2、 Deliberation at the meeting of the board of supervisors
(I) the proposal on granting restricted shares to incentive objects and reserving some restricted shares in the 2021 restricted stock incentive plan was reviewed and approved
Relevant instructions of the board of supervisors on whether the conditions for this partial reserved grant are met:
1. The incentive objects to be granted rights and interests this time have the qualifications specified in the company law, the articles of association and other laws, regulations and normative documents, and meet the conditions of incentive objects specified in the measures for the administration of equity incentive of listed companies (hereinafter referred to as the “administrative measures”) and the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, It complies with the scope of incentive objects specified in the 2021 restricted stock incentive plan (Draft) (hereinafter referred to as the “incentive plan”), and there are no independent directors and supervisors among the incentive objects. As the incentive object to be granted rights and interests this time, its subject qualification is legal and effective, and meets the conditions of being granted rights and interests.
2. The company and some of the incentive objects reserved for grant this time are not allowed to grant rights and interests, and the conditions for incentive objects to be granted rights and interests set by the company’s restricted stock incentive plan in 2021 have been met.
3. The company has determined that the granting date of some reserved restricted shares granted to the incentive objects in the restricted stock incentive plan in 2021 complies with the relevant provisions on the granting date in the administrative measures and the incentive plan.
Therefore, the board of supervisors agreed that the company set the reserved grant date of the restricted stock incentive plan in 2021 as February 16, 2022, and agreed to grant 427100 restricted shares to 33 eligible incentive objects at the grant price of 4 yuan / share.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on February 17, 2022 Announcement on granting restricted shares to incentive objects and reserving some restricted shares in the 2021 restricted stock incentive plan (Announcement No.: 2022-007). Voting results: 3 in favor, 0 against and 0 abstention. The proposal was deliberated and passed. It is hereby announced.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) board of supervisors of Pharmaceutical (Shanghai) Co., Ltd. February 17, 2022
